Mechanism of Action of Acamprosate. Part I. Characterization of Spermidine-Sensitive Acamprosate Binding Site in Rat Brain

Abstract

It has been suggested that the anticraving drug, acamprosate, acts via the glutamatergic system, but the exact mechanism of action is still unknown. The aim of this study was to characterize [3H]acamprosate binding and establish whether this showed any relation to sites on the NMDA receptor complex. We found saturable specific binding of [3H]acamprosate to rat brain membranes with a KD of 120 microM and a Bmax of 450 pmol/mg of protein. This acamprosate binding site was sensitive to inhibition by spermidine (IC50: 13.32 +/- 1.1 microM; Hill coefficient = 1.04), and arcaine and glutamate both potentiated the inhibitory effect of spermidine. Acamprosate binding to the acamprosate binding site was also sensitive to inhibition by divalent cations (Ca2+, Mg2+, and Sr2+). Conversely, acamprosate displaced [14C]spermidine binding from rat brain membranes with an IC50 of 645 microM and a Hill coefficient = 1.74. This inhibitory effect of acamprosate was not affected by arcaine, and was associated with a significant reduction in Bmax and binding affinity for spermidine, suggesting an allosteric interaction between acamprosate and a spermidine binding site. These data are consistent with an effect of acamprosate on the NMDA receptor protein complex, and acamprosate was also found to alter binding of [3H]dizocilpine to rat brain membranes. When no agonists were present in vitro (minimal NMDA receptor activation), acamprosate markedly potentiated [3H]dizocilpine binding at concentrations in the 5 to 200 microM range. However, under conditions of maximal receptor activation (100 microM glutamate, 30 microM glycine), acamprosate only inhibited [3H]dizocilpine binding (at concentrations concentrations >100 microM). When these binding studies were performed in the presence of 1 microM spermidine, the enhancing effects of acamprosate on [3H]dizocilpine binding were inhibited. The results show that acamprosate binds to a specific spermidine-sensitive site that modulates the NMDA receptor in a complex way. Together, with data from al Quatari et al. (see next paper), this work suggests that acamprosate acts as "partial co-agonist" at the NMDA receptor, so that low concentrations enhance activation when receptor activity is low, whereas higher concentrations are inhibitory to high levels of receptor activation. This may be relevant to the clinical effects of acamprosate in alcohol-dependent patients during abstinence.

Impact of acamprosate on plasma amyloid-β precursor protein in youth: A pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker

“…It is a novel agent with multiple potential mechanisms of action demonstrated in animal studies. Potential pharmacodynamic properties include attenuation of N-methyl-D-aspartate (NMDA) (Mayer et al 2002; Naassila et al 1998) and metabotropic type 5 glutamate receptor (mGluR5) (Blednov and Adron Harris 2008; Gupta et al 2008; Harris et al 2002; Kotlinska and Bochenski 2008) neurotransmission and agonist effects at gamma-aminobutyric acid type A (GABA(A)) neuroreceptors (Mann et al 2008; Pierrefiche et al 2004). The exact mechanisms of action of acamprosate remain unclear, in part, given results of an electrophysiology receptor binding study that noted no direct activity of acamprosate at glutamate or GABA receptors using clinically relevant drug concentrations (Reilly et al 2008).…”

High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects

“…Thus, it is possible this inhibition is due to toxicity. Acamprosate is a NMDA receptor modulator used to suppress cravings (Naassila et al, 1998). Acamprosate has been shown to inhibit microsomal Ca 2+− ATPase and leads to an increase in reactive oxygen species, which could affect mitochondrial function (Çalışkan et al, 2010).…”

Pharmacotherapy for Alcohol Use Disorder

“…55 Its mechanism of action is not completely understood, but acamprosate has inhibitory effects at the metabotropic glutamate receptor 5 (mGluR5) 56 and can reduce the elevated glutamate levels that are observed in individuals with severe AUD. Acamprosate binds to polyamine regulatory sites on NMDA receptors 57 and has both excitatory and inhibitory effects, depending upon experimental conditions. 58,59 In addition, Spanagel and colleagues 60 recently proposed that N-acetylhomotaurinate alone is not an active psychotropic molecule; rather, calcium is the active component, demonstrating anti-relapse effects.…”